Literature DB >> 32790101

Incidence and predictors of early and late hospital readmission after transurethral resection of the prostate: a population-based cohort study.

Samer Shamout1,2, Kevin Carlson1,2, Hilary L Brotherhood1, Trafford Crump1, Richard Baverstock1,2.   

Abstract

OBJECTIVES: To evaluate the incidence and predictors of hospital readmission and emergency department (ED) visits in patients with benign prostatic hyperplasia treated by transurethral resection of the prostate (TURP). PATIENTS AND METHODS: We conducted a retrospective cohort study using a linked administrative dataset from Calgary, Canada. Participants were men who underwent their first TURP procedure between 2015 and 2017. We examined patient demographics, and type of surgery (elective or urgent). Comorbidities were scored using the Charlson comorbidity index (CCI). The primary outcomes were unplanned hospital readmissions and ED visits at 30, 60 and 90 days after TURP. The secondary aim was to identify potential predictors across these groups.
RESULTS: We identified 3059 men, most of whom underwent elective TURP (83%). The mean (sd) patient age was 71.0 (10.0) years. A total of 224 patients (7.4%) were readmitted to the hospital within 30 days, 290 (9.5%) within 60 days, and 339 (11.1%) within 90 days of discharge. The frequency of return visits within 30, 60 and 90 days of TURP were 21.4%, 26% and 28.6%, respectively. The most responsible diagnoses for ED visit within 90 days were haematuria (15.4%) and retention of urine (12.8%). Multivariable analysis showed that age (odds ratio [OR] 1.61, P < 0.001), surgery type (OR 2.20, P < 0.001), and CCI score (OR 2.03, P < 0.001) were independently associated with odds of readmission and ED visits at all time points.
CONCLUSION: Older age, poorer health and urgent surgery predicted return to ED or readmission after TURP; efforts should be made to improve selection, counselling and preoperative optimization based on these risks.
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #UroBPH; patient readmission; prostatic hyperplasia; transurethral resection of prostate

Year:  2020        PMID: 32790101     DOI: 10.1111/bju.15191

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Effect of the Age-Adjusted Charlson Comorbidity Index on All-Cause Mortality and Readmission in Older Surgical Patients: A National Multicenter, Prospective Cohort Study.

Authors:  Xiao-Ming Zhang; Xin-Juan Wu; Jing Cao; Na Guo; Hai-Xin Bo; Yu-Fen Ma; Jing Jiao; Chen Zhu
Journal:  Front Med (Lausanne)       Date:  2022-06-28

2.  Risk Factors of Emergency Room Visits for Bleeding Complications Following Transurethral Procedures in the Treatment of Benign Prostatic Hyperplasia: A Retrospective Cohort Study.

Authors:  Tzu-Chi Teng; I-Hung Shao; Yu-Chao Hsu; Yu Chen; Shu-Han Tsao; Yen-Te Kang; Ming-Li Hsieh
Journal:  Clin Interv Aging       Date:  2021-09-29       Impact factor: 4.458

3.  The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Authors:  Henry H Woo; Chi-Ping Huang; William J Huang; Yi-Huei Chang; Chi-Shun Lien; Archil Chkhotua; Dean S Elterman
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-05-31       Impact factor: 5.455

4.  Comparison of Emergency Room Visits and Rehospitalization for Bleeding Complications following Transurethral Procedures for the Treatment of Benign Prostatic Hyperplasia: A Population-Based Retrospective Cohort Study.

Authors:  Shih-Liang Chen; Chih-Kai Hsu; Chun-Hsiang Wang; Che-Jui Yang; Ting-Jui Chang; Yu-Hsuan Chuang; Yuan-Tsung Tseng
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.